Pharmaceutical Patent
Pioneering Solutions in Drug Development.
Invention Patents
Innovative preparation methods for APIs and intermediates.
Utility Model Patents
Innovation and creation of pharmaceutical facilities and equipment.
Autonomous Patent Authorization
Independent ownership and control of patent rights.
Development of New Product
Implementation and improvement of production processes and methods.
Product Process Improvement
Improvement of existing product processes to meet more detailed needs.
Innovation Project Research
Host and conduct provincial-level technology innovation project research.
Patents in Pharmaceutical Industry
“We are committed to protecting our innovations through pharmaceutical
patents while ensuring that they benefit a wider patient population.”
Patents are the Cornerstone of Innovation in the Pharmaceutical Industry
We are well aware that every patent is a commitment to human health and an exploration of future possibilities. We are proud to announce that we have successfully transformed 27 invention patents and 40 new patents, which have not only promoted the progress of medical technology, but also benefited patients.
What did we do?
What's News
Latest News at Tianming
ICH Q11 Starting Material Selection: A Practical Guide for Pharmaceutical Intermediate Buyers
Learn how ICH Q11 starting material rules affect pharmaceutical intermediate sourcing—supplier boundaries, COA red flags, and a practical buyer’s checklist.
Polymorphism in Pharmaceutical Intermediates: Why Solid Form Control Matters
This guide explains what polymorphism means for intermediate buyers, how ICH Q6A Decision Tree #4 governs solid form control, which COA red flags signal polymorph gaps, and three questions every buyer should ask their supplier before committing to a purchase.
Elemental Impurities (ICH Q3D) in Pharmaceutical Intermediates: A Buyer’s Guide
This guide explains the four element classes, the 30% control threshold that determines whether routine testing is required, the difference between ICP-MS and ICP-OES analytical methods, and five red flags on supplier COAs that signal inadequate elemental impurity control.